Medicaid (general — varies by state)

How Medicaid (general — varies by state) approaches GLP-1 coverage

Medicaid is jointly funded by federal and state governments, but each state administers its own program — including its Preferred Drug List (PDL), prior authorization rules, and decisions on anti-obesity medications. Unlike Medicare Part D, Medicaid is NOT bound by a statutory weight-loss-drug exclusion; states have discretion under Social Security Act §1927(d)(2). As of 2025, roughly 16 state Medicaid programs cover GLP-1s for weight loss (subject to BMI thresholds, comorbidity requirements, and step therapy); the rest cover GLP-1s only for FDA-approved T2D indications. For T2D, coverage is broadly available when the drug is on the state PDL, though prior authorization, A1C documentation, and step therapy through metformin or sulfonylureas are routine. Managed Care Organizations (MCOs) administering Medicaid in many states may layer additional utilization controls on top of the state PDL. Dual-eligible (Medicare + Medicaid) members follow different rules. Always verify with your specific state Medicaid program and current formulary, as policies change frequently.

Statutory and structural notes

Social Security Act §1927(d)(2) permits — but does not require — state Medicaid programs to exclude drugs used for anorexia, weight loss, or weight gain. This is the statutory basis for state-by-state variance. Unlike Medicare Part D, no federal statute forces states to deny weight-loss drugs. The Treat and Reduce Obesity Act (TROA), a proposed federal bill, primarily affects Medicare — not Medicaid — and is not enacted as of 2026.

Typically considered for coverage

The list below reflects general patterns observed across Medicaid (general — varies by state)plan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.

• Ozempic for T2D when on the state Preferred Drug List and clinical criteria are met — verify with your specific state Medicaid formulary and current PDL
• Mounjaro for T2D when on the state PDL with prior authorization — verify with your specific state Medicaid formulary and current PDL
• Rybelsus (oral semaglutide) for T2D where preferred or non-preferred with PA — verify with your specific state Medicaid formulary and current PDL
• Wegovy or Zepbound for weight loss ONLY in the ~16 states that cover anti-obesity medications, subject to BMI and comorbidity criteria — verify with your specific state Medicaid program and current coverage policy

Typically excluded

• Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda) in the majority of state Medicaid programs that have elected the §1927(d)(2) exclusion
• Off-label use of T2D-indicated GLP-1s (Ozempic, Mounjaro) for weight loss without a documented T2D diagnosis
• Compounded semaglutide and tirzepatide — Medicaid generally does not reimburse compounded versions of FDA-approved drugs
• Coverage outside FDA-approved age ranges or without documented step therapy in states that require it

Prior authorization

Prior authorization is commonly required for GLP-1 medications under Medicaid (general — varies by state) plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.

Appeal strategy if denied

Request the written denial citing the specific PDL or PA criterion missed. File an internal appeal with the state Medicaid agency or MCO within the deadline (typically 60-90 days). Submit T2D diagnosis with A1C, prior trial/failure of preferred agents, BMI and comorbidities for weight-loss requests, and a prescriber letter of medical necessity. If denied internally, request a State Fair Hearing — a federal right under 42 CFR §431.200.

GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.